TABLE 1.
Demographic data and clinical characteristics of patients with STEMI.
| Characteristics | All patients (n = 92) | <Median MSI (n = 46) | ≥Median MSI (n = 46) | p-value |
| Age (years) | 59 ± 10 | 58 ± 11 | 59 ± 10 | 0.735 |
| Male gender, n (%) | 69 (75.0) | 37 (80.4) | 32 (69.6) | 0.229 |
| BMI (kg/m2) | 25.4 ± 3.9 | 25.8 ± 4.2 | 25.0 ± 3.7 | 0.354 |
| Symptom onset to reperfusion (min) | 240 (180–420) | 330 (180–480) | 180 (120–360) | 0.001 |
| PPCI to CMR (days) | 3.9 (3.0–4.8) | 3.6 (3.0–4.7) | 4.0 (3.0–4.9) | 0.316 |
| Medical history | ||||
| Hypertension, n (%) | 31 (33.7) | 16 (34.8) | 15 (32.6) | 0.825 |
| Smoking, n (%) | 41 (44.6) | 21 (45.7) | 20 (43.5) | 0.834 |
| Diabetes mellitus, n (%) | 13 (14.1) | 5 (10.9) | 6 (17.4) | 0.369 |
| Culprit coronary artery | 0.641 | |||
| LAD, n (%) | 47 (51.1) | 22 (47.8) | 25 (54.3) | |
| RCA, n (%) | 3 (3.3) | 1 (2.2) | 2 (4.3) | |
| LCX, n (%) | 42 (45.7) | 23 (50.0) | 19 (41.3) | |
| Initial blood results on admission | ||||
| NT-proBNP (pg/mL) | 351.5 (101.0–1110.3) | 334.5 (97.5–823.8) | 405.0 (100.8–1422.5) | 0.380 |
| Peak troponin I, (ng/mL) | 29.7 (8.9–107.0) | 18.2 (6.7–85.5) | 44.9 (11.7–117.2) | 0.120 |
| Cholesterol | 4.8 ± 1.1 | 5.1 ± 1.1 | 4.6 ± 1.0 | 0.021 |
| Medications post-PPCI | ||||
| ACE-I or ARB, n (%) | 50 (54.3) | 26 (56.5) | 24 (52.2) | 0.675 |
| Beta blocker, n (%) | 63 (68.5) | 29 (63.0) | 34 (73.9) | 0.262 |
| Statins, n (%) | 90 (97.8) | 45 (97.8) | 45 (97.8) | 1.000 |
| Aspirin, n (%) | 92 (100.0) | 46 (100.0) | 46 (100.0) | 1.000 |
| Nitrates, n (%) | 30 (32.6) | 10 (21.7) | 20 (43.5) | 0.026 |
| Clopidogrel, n (%) | 87 (94.6) | 44 (95.7) | 43 (93.5) | 1.000 |
| Ticagrelor, n (%) | 3 (3.3) | 1 (2.2) | 2 (4.3) | 1.000 |
P < 0.05 is considered to indicate statistical significance. STEMI, ST-segment elevation myocardial infarction; MSI, myocardial salvage index; BMI, body mass index; LAD, left anterior descending; RCA, right coronary artery; LCX, left circumflex artery, NT-proBNP, N-terminal pro-B type natriuretic peptide; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.